Core Insights - The latest net value of Zhongyin Innovation Medical Mixed A (007718) is 2.1723 yuan, reflecting a decline of 3.54%. The fund has shown a one-month return of 12.66%, a six-month return of 78.76%, and a year-to-date return of 80.53% [1]. Fund Performance - The fund ranks 684 out of 4457 in the one-month category, 23 out of 4316 in the six-month category, and 29 out of 4287 in the year-to-date category [1]. Holdings Overview - The top ten stock holdings of Zhongyin Innovation Medical Mixed A account for a total of 62.83%, with significant positions in companies such as: - Innovent Biologics (8.33%) - Kelun-Biotech (8.15%) - Heng Rui Medicine (8.08%) - CanSino Biologics (8.07%) - New Horizon Health (6.13%) - Bai Li Tianheng (5.99%) - BeiGene (5.97%) - Hansoh Pharmaceutical (4.15%) - Rongchang Biologics (4.05%) - CanSino Biologics-B (3.91%) [1]. Fund Manager Background - Zheng Ning, the fund manager, has a master's degree and has previously held positions at Taikang Asset Management and Zhonggeng Fund Management. He joined Zhongyin Fund Management in 2022 and has been managing the Zhongyin Innovation Medical Mixed Fund since July 1, 2022 [2].

金融界2025年8月7日消息，中欧医疗创新股票A(006228) 最新净值1.6940元，下跌3.58%。该基金近1个 月收益率16.92%，同类排名25|614；近6个月收益率60.72%，同类排名16|591；今年来收益率62.92%， 同类排名17|589。 中欧医疗创新股票A股票持仓前十占比合计64.06%，分别为：三生制药（8.99%）、科伦博泰生 （8.52%）、康方生物（8.20%）、药明合联（6.98%）、药明生物（6.04%）、百利天恒（5.89%）、药 明康德（5.63%）、凯莱英（5.21%）、新诺威（4.61%）、恒瑞医药（3.99%）。 公开资料显示，中欧医疗创新股票A基金成立于2019年2月28日，截至2025年6月30日，中欧医疗创新股 票A规模48.74亿元，基金经理为葛兰。 简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 活配置 ...

8月7日恒生指数上涨0.69%，南向资金全天合计成交金额为1407.38亿港元，其中，买入成交707.00亿港 元，卖出成交700.38亿港元，合计净买入金额6.61亿港元。具体来看，港股通（深）累计成交金额 526.81亿港元，买入成交283.53亿港元，卖出成交243.29亿港元，合计净买入金额40.24亿港元；港股通 （沪）累计成交金额880.57亿港元，买入成交423.47亿港元，卖出成交457.10亿港元，合计净卖出金额 33.63亿港元。 | 代码 | 简称 | 成交金额（万港元） | 成交净买入（万港元） | 今日涨跌幅（%） | | --- | --- | --- | --- | --- | | 01810 | 小米集团-W | 1047772.68 | 172172.52 | -3.98 | | 00981 | 中芯国际 | 426693.35 | 49971.98 | 0.76 | | 09988 | 阿里巴巴-W | 443298.37 | 49292.76 | 2.14 | | 00700 | 腾讯控股 | 377791.38 | 42667.88 | -0.26 | | 01347 ...

（文章来源：证券时报网） 康方生物获南向资金连续3天净买入，累计净买入金额为6.74亿港元，股价累计上涨3.48%。 8月7日上榜的成交活跃股中，康方生物通过港股通渠道成交金额为11.38亿港元，净买入金额为2.46亿港 元，不仅如此，该股已连续3日出现成交净买入，累计净买入金额为6.74亿港元，其间股价上涨3.48%。 （数据宝） 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 证券时报·数据宝统计显示，8月7日港股通（包括沪市港股通及深市港股通）成交活跃股合计成交437.22 亿港元，净卖出金额为8.01亿港元。 ...

Market Overview - The Hong Kong stock market experienced fluctuations but closed higher, with the Hang Seng Index rising by 0.69% to 25081.63 points, the Hang Seng Tech Index increasing by 0.26% to 5546.73 points, and the Hang Seng China Enterprises Index up by 0.55% to 8981.73 points [1] Apple-Related Stocks - Apple-related stocks were boosted, with notable gains in companies such as Gao Wei Electronics, which rose by 9.62%, and Sunny Optical Technology, which increased by 3.30% [4] - The positive sentiment was driven by President Trump's announcement of a 100% tariff on imported semiconductors, exempting companies manufacturing in the U.S. [4] - Apple announced a new $100 billion investment plan in the U.S., increasing its total investment to $600 billion over four years, which is expected to positively impact related stocks [5] Semiconductor Sector - Semiconductor stocks also saw gains, with Huahong Semiconductor and SMIC rising by 2.52% and 0.76%, respectively [5][6] Gaming Sector - The gaming sector continued to rise, with companies like China Star Group and Sands China increasing by 7.43% and 5.01%, respectively [7][8] - Macau's gaming revenue for July reached 22.125 billion MOP, a year-on-year increase of 19%, marking a post-pandemic high [8] Real Estate Sector - The real estate sector showed signs of recovery, with New World Development rising by over 10% and other companies like Wharf Holdings and China Jinmao increasing by over 3% [10][11] - Recent policy adjustments in core cities are expected to support the real estate market, focusing on stabilizing measures [11] Pharmaceutical Sector - The pharmaceutical sector faced pressure, with companies like CanSino Biologics and Innovent Biologics experiencing declines of 8.06% and 7.16%, respectively [12][13] - President Trump's upcoming announcement regarding new tariffs on pharmaceuticals is contributing to the sector's downturn [12] Cao Cao Mobility - Cao Cao Mobility saw a significant increase of over 18% following the announcement of a strategic cooperation with Victory Securities regarding virtual asset collaboration [14][16]

Investment Rating - The report suggests a cautious subscription for the company [2]. Core Insights - The company focuses on the research and commercialization of drugs for diabetes (T2D) and obesity, with its core product being Isuparaglutide α, which received NMPA approval in January 2025 and was launched in China in February 2025 [2][4]. - The company has a comprehensive pipeline targeting metabolic diseases, including other candidates like YN202, YN203, and YN209 [2]. - The global obesity/overweight drug market is projected to grow to USD 36.9 billion from 2024 to 2028, with a CAGR of 21.5%, while the Chinese market is expected to reach RMB 12.2 billion with a CAGR of 30.6% during the same period [3]. - The company reported revenue of RMB 38.1 million for the five months ending May 31, 2025, with a gross margin of 89.3% [4]. Summary by Sections IPO Details - The company plans to raise HKD 610 million through its IPO, with a share price of HKD 18.68 and a total offering of 3,655,000 shares [1]. Financial Performance - The company recorded a net loss of RMB 175 million in 2024, indicating it is still in a loss-making phase despite being in a rapidly growing market [4]. Market Potential - The Chinese GLP-1 receptor agonist market is expected to grow from RMB 400 million to RMB 9.5 billion from 2024 to 2028, with a CAGR of 123.3% [3].

Group 1 - Xiaomi Group-W (01810) leads the southbound trading volume on both Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, with transaction amounts of 62.12 billion and 42.66 billion respectively [1][1][1] - The top three companies by trading volume on Shanghai-Hong Kong Stock Connect are Xiaomi Group-W (01810), Yingfu Fund (02800), and Alibaba-W (09988) [1][1] - On Shenzhen-Hong Kong Stock Connect, the top three companies are Xiaomi Group-W (01810), SMIC (00981), and Alibaba-W (09988) [1][1] Group 2 - The net buying amount for Xiaomi Group-W (01810) on Shanghai-Hong Kong Stock Connect is +17.67 billion, while on Shenzhen-Hong Kong Stock Connect it is -45.59 million [1][1] - Alibaba-W (09988) has a net buying amount of +3.25 billion on Shanghai-Hong Kong Stock Connect and +1.68 billion on Shenzhen-Hong Kong Stock Connect [1][1] - SMIC (00981) shows a significant net buying amount of +5.26 billion on Shenzhen-Hong Kong Stock Connect, while it has a net buying amount of -25.94 million on Shanghai-Hong Kong Stock Connect [1][1]

Core Views - The opportunity cost of equity investment remains low, with a downward trend in interest rates since September last year, enhancing the attractiveness of stock investments compared to other asset classes [2][78]. - The real estate risks that began to unfold in 2021 have not yet fully stabilized, indicating that the adjustment in the national real estate market is still ongoing [2][11]. - China has a comparable gap with the US in the AI technology revolution, with advantages in application, potentially outperforming any other country in practical implementation [2][51]. - Chinese companies must transition to a phase where they gain more added value through branding and enhance the technological content of their products [2][66]. - The view on technology stocks is still cautious, described as a "game for the brave," emphasizing the need for risk awareness and contingency plans [2][90]. Economic Growth Model - China's past economic growth model is becoming ineffective, necessitating reforms, particularly the transition from an investment-driven government to a service-oriented government [4][19]. - The challenges in this transition include high levels of local government debt and the inefficiency of past investments, which have led to diminishing returns [21][23]. - The future direction of economic growth will likely rely more on consumption to drive growth, with a significant focus on the service sector to address employment issues [26][29]. Real Estate Sector - Since 1998, approximately 500 billion square meters of commercial housing stock has been accumulated, with a significant portion of household wealth tied up in real estate [11]. - The average national price of real estate is around 10,000 yuan per square meter, indicating that the wealth of households in real estate amounts to approximately 500 trillion yuan [11]. - The real estate market is still facing downward pressure, with sales volumes declining from a peak of 1.56 billion square meters in 2021 to over 800 million square meters in 2024 [38][39]. - The rental yield is a crucial factor in stabilizing real estate prices, with a target yield of around 2% being necessary for long-term stability [42][43]. Technology Sector - The technology sector has shown significant growth since 2018, particularly in the context of US-China decoupling, necessitating self-reliance in technology development [12][15]. - The biopharmaceutical sector has been a standout performer, with Chinese companies increasingly contributing to global drug development [48][49]. - Despite challenges, China's manufacturing sector remains robust, with a strong supply chain and cost advantages that are difficult for other countries to replicate [17][71]. Manufacturing Sector - Manufacturing is considered the foundation of China's economic strength, with historical examples showing that countries that neglect manufacturing tend to decline [16]. - The focus for Chinese manufacturers should shift towards increasing product value through R&D and branding, moving away from a volume-driven model [66]. - The impact of tariffs on manufacturing is manageable for many companies, with strategies in place to mitigate costs and maintain competitiveness [70]. Investment Strategy - The current investment strategy emphasizes maintaining a high allocation in equities, particularly in dividend-paying stocks and technology, while being cautious about market conditions [76][89]. - The portfolio is diversified, with approximately 40% in dividend assets, 30% in technology stocks, and over 20% in manufacturing [92][98]. - The focus on Hong Kong stocks is driven by their relative affordability and the broader range of investment opportunities available compared to the domestic market [83][84].

| 代码 | 简称 | 收盘价 (港元) | 涨跌幅 (%) | 净买入金额 (亿港元) | | | --- | --- | --- | --- | --- | --- | | 1810.HK | 小米集团-W | 51.85 | -3.98 | 17.22 | . | | 0981.HK | 中芯国际 | 53.0 | 0.76 | 5.00 | . | | 9988.HK | 阿里巴巴-W | 119.2 | 2.14 | 4.93 | . | | 0700.HK | 腾讯控股 | 567.0 | -0.26 | 4.27 | . | | 1347.HK | 华虹半导体 | 44.78 | 2.52 | 3.73 | | | 9926.HK | 康方生物 | 157.4 | -8.06 | 2.46 | . | | 1093.HK | 石药集团 | 9.68 | -3.78 | 1.84 | = | | 6181.HK | 老铺黄金 | 794.5 | 3.45 | 1.67 | . | | 1801.HK | 信达生物 | 91.4 | -6.78 | 1.22 | . | | 2228.HK | 晶泰 ...

Group 1: Market Activity - Net purchases included Xiaomi Group-W at 1.722 billion, SMIC at 499 million, Alibaba-W at 492 million, Tencent Holdings at 426 million, and Huahong Semiconductor at 372 million [1] - Southbound funds have net bought Tencent for 11 consecutive days, totaling 6.3707 billion HKD; Alibaba for 4 consecutive days, totaling 2.60865 billion HKD; and SMIC for 4 consecutive days, totaling 1.45077 billion HKD [1] Group 2: Company Performance - Xiaomi Group-W is expected to report Q2 2025 earnings on August 19, with smartphone shipments projected to be slightly below previous forecasts, primarily due to a 25% year-on-year decline in the Indian market; global market share reached a historical high of 15% at the cost of declining gross margins [5] - SMIC reported Q2 revenue of 2.209 billion USD, a year-on-year increase of 16.2% but a quarter-on-quarter decrease of 1.7%; Q3 revenue is expected to grow by 5%-7% quarter-on-quarter, with gross margin projected between 18%-20% [6] - Alibaba-W's Tongyi Qianwen released new smaller models, indicating ongoing innovation in AI [6] - Morgan Stanley noted that Pop Mart's platform value may be underestimated, highlighting potential for cultural diversity in its IP and product offerings over the next 3-5 years [6]